GSK Stock Analysis: Buy, Sell, or Hold?
GSK - GSK plc American Depositary Shares (Each representing two Ordinary Shares)
$51.21
1.19 (2.38%)
▲
5d:
+4.47%
30d:
+3.02%
90d:
-0.27%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Oct 28, 2026
4d
Get Alerted When GSK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: GSK shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: GSK shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$62.14
Based on 4.1% avg growth
INTRINSIC VALUE TODAY
$38.58
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GSK is currently trading at $51.21, which is considered extended relative to its 30-day fair value range of $47.26 to $50.50. The stock's valuation (Forward PE: 10.4) is in line with its historical norms (10.3). At these levels, the market is pricing in 0.3% annual earnings growth.
Technical Outlook: Technically, GSK is in a downtrend. The price is approaching resistance at $51.44. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GSK scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $60.51 (+18.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GSK is in a downtrend. The price is approaching resistance at $51.44. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GSK scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $60.51 (+18.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$47.26 -
$50.50
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
29.5%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($60.51)
- BULLISH: Expecting earnings turnaround to 0.3% growth with 5.3% revenue growth
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$47.26 -
$50.50
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$46.11
Resistance Level
$51.44
Current Trend
Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.40
Wall Street Target
$60.51
(+18.2%)
Revenue Growth (YoY)
5.3%
Earnings Growth (YoY)
-69.5%
Profit Margin
14.5%
Valuation Premium vs History
+0.3% premium
PE vs Historical
10.4 vs 10.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.3%
(market-implied from PE analysis)
1-Year Target
$51.36
(+0%)
2-Year Target
$51.52
(+1%)
3-Year Target
$51.67
(+1%)
3-Yr Target (if PE normalizes)
(PE: 10→10)
PE COMPRESSION
$51.17
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 4.3%)
$110.96
(+117%)
Base:
(SPY PE: 10.4, Growth: 4.3%)
$58.12
(+14%)
Bear:
(PE: 8.8, Growth: 4.3%)
$49.40
(-4%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 15.78 | Current EPS (TTM): $3.17
Bull Case
$85.45
(+67%)
Analyst growth 55.3%, PE expands to 17.4
Base Case
$77.68
(+52%)
Market implied 55.3%, PE stable at 15.8
Bear Case
$34.01
(-34%)
Severe decline -20.0%, PE contracts to 13.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 23, 2026 6:49 AM ET
Data refreshes hourly during market hours. Next update: 7:49 AM
Data refreshes hourly during market hours. Next update: 7:49 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GSK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ABBV
AbbVie Inc |
STRONG BUY
30 analysts |
$283 | 44 HOLD |
|
GILD
Gilead Sciences Inc |
STRONG BUY
28 analysts |
$160 | 43 HOLD |
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1328 | 27 SELL |
|
BIIB
Biogen Inc |
BUY
36 analysts |
$244 | 39 SELL |
|
MRK
Merck & Company Inc |
STRONG BUY
27 analysts |
$158 | 43 HOLD |
